PWPS
CRSP icon

Pinnacle Wealth Planning Services’s CRISPR Therapeutics CRSP Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.44K Sell
118
-42
-26% -$2.21K ﹤0.01% 2230
2026
Q1 		$7.61K Sell
160
-1
-0.6% -$53 ﹤0.01% 2117
2025
Q4 		$8.44K Buy
+161
New +$9.64K ﹤0.01% 2077

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pinnacle Wealth Planning Services's CRSP Position: Q2 2026 in Review

Pinnacle Wealth Planning Services reduced its CRISPR Therapeutics (CRSP) stake by 26% in Q2 2026, selling an estimated $2.21K and leaving 118 shares worth $6.44K. The position accounts for ﹤0.01% of the portfolio, ranked #2230.

Pinnacle Wealth Planning Services first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.44K in Q4 2025. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Pinnacle Wealth Planning Services held 118 shares of CRISPR Therapeutics worth $6.44K as of Q2 2026.
  • Pinnacle Wealth Planning Services sold 42 CRISPR Therapeutics shares in Q2 2026, an estimated $2.21K.
  • CRISPR Therapeutics made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q2 2026, its #2230 holding.
  • Pinnacle Wealth Planning Services first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Pinnacle Wealth Planning Services's CRISPR Therapeutics position peaked at $8.44K in Q4 2025.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q2 2026, filed 7 Aug 2026.